Approach to JCV testing with natalizumab biosimilar: a UK consensus statement

Dobson, Ruth, Arun, Tarunya, Varley, James, Chataway, Jeremy, Brownlee, Wallace, Gallagher, Paul, Giovannoni, Gavin, Gray, Orla, Ingram, Gillian, MacDougall, Niall, Muraro, Paolo, Murray, Katy, Paling, David, Petheram, Kate, Rashid, Waqar, Tallantyre, Emma ORCID: https://orcid.org/0000-0002-3760-6634, Trip, S. Anand and Coles, Alasdair 2025. Approach to JCV testing with natalizumab biosimilar: a UK consensus statement. Multiple Sclerosis and Related Disorders 100 , 106541. 10.1016/j.msard.2025.106541

PDF - Published Version Available under License Creative Commons Attribution. Download (398kB)

Abstract

Biosimilars have an important role to play in healthcare, with the potential to reduce costs and widen access to treatment. We welcome the use of biosimilars in the treatment of multiple sclerosis. Serological testing for JC virus is mandated as part of safety monitoring in those treated with natalizumab. All PML risk stratification data to date has come from the use of the “Stratify” JC virus (JCV) serostatus test. The “Immunowell” test used to define JCV serostatus (used with Tyruko) does not always give equivalent results to the Stratify test (used with Tysabri), particularly around thresholds used to define risk of progressive multifocal leukoencephalopathy (PML). In comparison to the Stratify test, Immunowell appears more likely to report a positive JCV index. However, negative results using Immunowell show a high rate of agreement with Stratify, which allows for a rational safety strategy. There remains a real risk that a proportion of patients will be inappropriately classified as being at higher risk of PML, and therefore denied the option of natalizumab, a highly effective therapy, or undergo unnecessarily burdensome monitoring, with resultant cost to the NHS and anxiety. We provide guidance for patients with discordant results between assays, aiming to balance the need for rigorous safety monitoring with patient access to highly effective therapy and unnecessary monitoring burden on healthcare services.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Publisher:	Elsevier
ISSN:	2211-0348
Date of First Compliant Deposit:	18 June 2025
Date of Acceptance:	21 May 2025
Last Modified:	18 Jun 2025 10:32
URI:	https://orca.cardiff.ac.uk/id/eprint/178917

Actions (repository staff only)

Edit Item